ephrin receptor a2  (R&D Systems)

Journal: Oncology Letters

Article Title: RNA methyltransferase NSUN2 enhances vasculogenic mimicry and malignant progression of cervical cancer through upregulation of MMP-9

doi: 10.3892/ol.2026.15518

Figure Lengend Snippet: MMP-9 , a factor that promotes Vasculogenic mimicry, is highly expressed in CC and is associated with poor prognosis. (A) CC database of TCGA was used to analyze key factors associated with VM. (B) Association of Sox2 expression with overall survival in CC (log-rank test). (C) Association of MMP-9 expression with overall survival in CC (log-rank test). (D) Panoramic scans after immunohistochemical detection of MMP-9 and H&E staining in samples from cancerous and paracancerous tissues from subjects with CC. Scale bar, 50 µm. Original magnification, ×20. (E) Protein levels of MMP-9 in 20 paired samples, with the MMP-9 level in CC tissue expressed compared with that in the paired normal tissue. (F) Expression levels of MMP-9 mRNA in 44 paired CC and paracancerous tissues, with MMP-9 expression in CC tissue expressed compared with that in the paired normal tissue. (G) Comparison of the average expression levels of MMP-9 mRNA in CC tissues compared with paracancerous tissues. (H) HeLa and SiHa cells were incubated under hypoxia (0.1% O 2 ) and proteins collected at 24, 48 and 72 h for western blotting of ALDH1, EPHA2, MMP-9 and GAPDH. ImageJ was used to semi-quantify western blotting signals from HeLa (I) and SiHa (J) cells. GAPDH served as an internal reference. *P<0.05, **P<0.01 and ***P<0.001. MMP-9, matrix metalloproteinase 9; VM, vasculogenic mimicry; ALDH1, aldehyde dehydrogenase 1; EPHA2, ephrin type-A receptor 2; TCGA, The Cancer Genome Atlas; Sox2, SRY-box transcription factor 2; CC, cervical cancer; CESC, cervical squamous cell carcinoma.

Article Snippet: The membranes were blocked with 5% milk at 20±5°C for 1 h. The blocked membranes were incubated at 4°C overnight with the following antibodies: A rabbit monoclonal anti-NSUN2 antibody (1:1,000; cat. no. AB259941; Abcam), a rabbit monoclonal anti-transfer RNA aspartic acid methyltransferase 1 (TRDMT1) antibody (1:1,000; cat. no. 19221-1-AP; Proteintech Group, Inc.; Wuhan Sanying Biotechnology), a rabbit polyclonal anti-MMP-9 antibody (1:1,000; cat. no. 10375-2-AP; Proteintech Group, Inc.; Wuhan Sanying Biotechnology), a rabbit polyclonal anti-aldehyde dehydrogenase 1 (ALDH1) antibody (1:1,000; cat. no. 15910-1-AP; Proteintech Group, Inc.; Wuhan Sanying Biotechnology), a rabbit polyclonal anti-ephrin type-A receptor 2 (EPHA2) antibody (1:1,000; cat. no. AF5 238; Affinity Biosciences) and a rabbit polyclonal anti-GAPDH antibody (1:1,000; TA309157 OriGene Technologies, Inc.).

Techniques: Expressing, Immunohistochemical staining, Staining, Comparison, Incubation, Western Blot

Journal: Diagnostics

Article Title: Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone

doi: 10.3390/diagnostics11071249

Figure Lengend Snippet: Demographics, clinical characteristics, and biomarkers on ICU admission, and ICU-related parameters.

Article Snippet: The following markers were measured concurrently in samples obtained on ICU admission by enzyme-linked immunosorbent assay (ELISA; the ELISA kits chosen had been previously used and validated in our laboratory): Transmembrane protein 173 (TMEM173) (Wuhan Fine Biotech Co., Ltd., Wuhan, China, intra-assay coefficient of variability (CV) < 8%, detection limit 0.094 ng/mL); triggering receptor expressed on myeloid cells-1 (TREM-1) (R&D Systems Inc., Minneapolis, MN, USA, CV 3.4%, detection limit 15.2 pg/mL); presepsin (Wuhan Fine Biotech Co., CV < 8%, detection limit < 0.094 ng/mL); CD40 ligand (CD40L) (R&D Systems Inc., CV 5.1%, detection limit 10.1 pg/mL); plasminogen (Wuhan Fine Biotech Co., CV < 8%, detection limit < 46.875 pg/mL); plasminogen activator inhibitor-1 (PAI-1) (R&D Systems Inc., CV 6.7%, detection limit 0.142 ng/mL); platelet factor 4 (PF4) (R&D Systems Inc., CV 7%, detection limit 0.1 ng/mL); soluble vascular cell adhesion molecule-1 (sVCAM-1) (R&D Systems Inc., CV 3.1%, detection limit 1.26 ng/mL); soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) (R&D Systems Inc., CV 3.4%, detection limit 0.075 ng/mL); endothelial cell specific molecule 1 (ESM-1, or endocan) (OriGene Technologies, Inc., Rockville, MD, USA, CV 4.4%, detection limit < 10 pg/mL); ephrin-A1 (Wuhan Fine Biotech Co., CV < 8%, detection limit 0.094 ng/mL); ephrin receptor A2 (EphA2) (Wuhan Fine Biotech Co., CV < 8%, detection limit 46.875 pg/mL); and soluble urokinase-type plasminogen activator receptor (suPAR) (R&D Systems Inc., CV 4.6%, detection limit 33 pg/mL).

Techniques: Cell Counting

Journal: Diagnostics

Article Title: Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone

doi: 10.3390/diagnostics11071249

Figure Lengend Snippet: Intensive care unit (ICU) admission levels of endothelial dysfunction biomarkers in COVID-19 patients. ( A ) Endocan, ( B ) Ephrin-A1, and ( C ) EphA2 were measured in 37 dexamethasone-free and 29 dexamethasone-treated (first dose—6 mg) critically ill patients upon ICU admission (within 24 h) (upper panels). The two patient groups were subsequently categorized as survivors and non-survivors (lower panels). Two-group comparisons were performed with the non-parametric Mann–Whitney test, ** p < 0.01, **** p < 0.0001. Data are presented as scatter plots, indicating the median value and 25 to 75 centiles. Dashed lines, median values of the dexamethasone-free group. DXM = Dexamethasone; EphA2 = Ephrin receptor A2.

Article Snippet: The following markers were measured concurrently in samples obtained on ICU admission by enzyme-linked immunosorbent assay (ELISA; the ELISA kits chosen had been previously used and validated in our laboratory): Transmembrane protein 173 (TMEM173) (Wuhan Fine Biotech Co., Ltd., Wuhan, China, intra-assay coefficient of variability (CV) < 8%, detection limit 0.094 ng/mL); triggering receptor expressed on myeloid cells-1 (TREM-1) (R&D Systems Inc., Minneapolis, MN, USA, CV 3.4%, detection limit 15.2 pg/mL); presepsin (Wuhan Fine Biotech Co., CV < 8%, detection limit < 0.094 ng/mL); CD40 ligand (CD40L) (R&D Systems Inc., CV 5.1%, detection limit 10.1 pg/mL); plasminogen (Wuhan Fine Biotech Co., CV < 8%, detection limit < 46.875 pg/mL); plasminogen activator inhibitor-1 (PAI-1) (R&D Systems Inc., CV 6.7%, detection limit 0.142 ng/mL); platelet factor 4 (PF4) (R&D Systems Inc., CV 7%, detection limit 0.1 ng/mL); soluble vascular cell adhesion molecule-1 (sVCAM-1) (R&D Systems Inc., CV 3.1%, detection limit 1.26 ng/mL); soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) (R&D Systems Inc., CV 3.4%, detection limit 0.075 ng/mL); endothelial cell specific molecule 1 (ESM-1, or endocan) (OriGene Technologies, Inc., Rockville, MD, USA, CV 4.4%, detection limit < 10 pg/mL); ephrin-A1 (Wuhan Fine Biotech Co., CV < 8%, detection limit 0.094 ng/mL); ephrin receptor A2 (EphA2) (Wuhan Fine Biotech Co., CV < 8%, detection limit 46.875 pg/mL); and soluble urokinase-type plasminogen activator receptor (suPAR) (R&D Systems Inc., CV 4.6%, detection limit 33 pg/mL).

Techniques: MANN-WHITNEY

Journal: Diagnostics

Article Title: Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone

doi: 10.3390/diagnostics11071249

Figure Lengend Snippet: Demographics, clinical characteristics and biomarkers on ICU admission in the dexamethasone-free group.

Article Snippet: The following markers were measured concurrently in samples obtained on ICU admission by enzyme-linked immunosorbent assay (ELISA; the ELISA kits chosen had been previously used and validated in our laboratory): Transmembrane protein 173 (TMEM173) (Wuhan Fine Biotech Co., Ltd., Wuhan, China, intra-assay coefficient of variability (CV) < 8%, detection limit 0.094 ng/mL); triggering receptor expressed on myeloid cells-1 (TREM-1) (R&D Systems Inc., Minneapolis, MN, USA, CV 3.4%, detection limit 15.2 pg/mL); presepsin (Wuhan Fine Biotech Co., CV < 8%, detection limit < 0.094 ng/mL); CD40 ligand (CD40L) (R&D Systems Inc., CV 5.1%, detection limit 10.1 pg/mL); plasminogen (Wuhan Fine Biotech Co., CV < 8%, detection limit < 46.875 pg/mL); plasminogen activator inhibitor-1 (PAI-1) (R&D Systems Inc., CV 6.7%, detection limit 0.142 ng/mL); platelet factor 4 (PF4) (R&D Systems Inc., CV 7%, detection limit 0.1 ng/mL); soluble vascular cell adhesion molecule-1 (sVCAM-1) (R&D Systems Inc., CV 3.1%, detection limit 1.26 ng/mL); soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) (R&D Systems Inc., CV 3.4%, detection limit 0.075 ng/mL); endothelial cell specific molecule 1 (ESM-1, or endocan) (OriGene Technologies, Inc., Rockville, MD, USA, CV 4.4%, detection limit < 10 pg/mL); ephrin-A1 (Wuhan Fine Biotech Co., CV < 8%, detection limit 0.094 ng/mL); ephrin receptor A2 (EphA2) (Wuhan Fine Biotech Co., CV < 8%, detection limit 46.875 pg/mL); and soluble urokinase-type plasminogen activator receptor (suPAR) (R&D Systems Inc., CV 4.6%, detection limit 33 pg/mL).

Techniques: Cell Counting

Journal: Diagnostics

Article Title: Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone

doi: 10.3390/diagnostics11071249

Figure Lengend Snippet: Demographics, clinical characteristics and biomarkers on ICU admission in the dexamethasone-treated group.

Article Snippet: The following markers were measured concurrently in samples obtained on ICU admission by enzyme-linked immunosorbent assay (ELISA; the ELISA kits chosen had been previously used and validated in our laboratory): Transmembrane protein 173 (TMEM173) (Wuhan Fine Biotech Co., Ltd., Wuhan, China, intra-assay coefficient of variability (CV) < 8%, detection limit 0.094 ng/mL); triggering receptor expressed on myeloid cells-1 (TREM-1) (R&D Systems Inc., Minneapolis, MN, USA, CV 3.4%, detection limit 15.2 pg/mL); presepsin (Wuhan Fine Biotech Co., CV < 8%, detection limit < 0.094 ng/mL); CD40 ligand (CD40L) (R&D Systems Inc., CV 5.1%, detection limit 10.1 pg/mL); plasminogen (Wuhan Fine Biotech Co., CV < 8%, detection limit < 46.875 pg/mL); plasminogen activator inhibitor-1 (PAI-1) (R&D Systems Inc., CV 6.7%, detection limit 0.142 ng/mL); platelet factor 4 (PF4) (R&D Systems Inc., CV 7%, detection limit 0.1 ng/mL); soluble vascular cell adhesion molecule-1 (sVCAM-1) (R&D Systems Inc., CV 3.1%, detection limit 1.26 ng/mL); soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) (R&D Systems Inc., CV 3.4%, detection limit 0.075 ng/mL); endothelial cell specific molecule 1 (ESM-1, or endocan) (OriGene Technologies, Inc., Rockville, MD, USA, CV 4.4%, detection limit < 10 pg/mL); ephrin-A1 (Wuhan Fine Biotech Co., CV < 8%, detection limit 0.094 ng/mL); ephrin receptor A2 (EphA2) (Wuhan Fine Biotech Co., CV < 8%, detection limit 46.875 pg/mL); and soluble urokinase-type plasminogen activator receptor (suPAR) (R&D Systems Inc., CV 4.6%, detection limit 33 pg/mL).

Techniques: Cell Counting

Journal: Diagnostics

Article Title: Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone

doi: 10.3390/diagnostics11071249

Figure Lengend Snippet: Characteristics of the biomarkers measured in the study cohort.

Article Snippet: The following markers were measured concurrently in samples obtained on ICU admission by enzyme-linked immunosorbent assay (ELISA; the ELISA kits chosen had been previously used and validated in our laboratory): Transmembrane protein 173 (TMEM173) (Wuhan Fine Biotech Co., Ltd., Wuhan, China, intra-assay coefficient of variability (CV) < 8%, detection limit 0.094 ng/mL); triggering receptor expressed on myeloid cells-1 (TREM-1) (R&D Systems Inc., Minneapolis, MN, USA, CV 3.4%, detection limit 15.2 pg/mL); presepsin (Wuhan Fine Biotech Co., CV < 8%, detection limit < 0.094 ng/mL); CD40 ligand (CD40L) (R&D Systems Inc., CV 5.1%, detection limit 10.1 pg/mL); plasminogen (Wuhan Fine Biotech Co., CV < 8%, detection limit < 46.875 pg/mL); plasminogen activator inhibitor-1 (PAI-1) (R&D Systems Inc., CV 6.7%, detection limit 0.142 ng/mL); platelet factor 4 (PF4) (R&D Systems Inc., CV 7%, detection limit 0.1 ng/mL); soluble vascular cell adhesion molecule-1 (sVCAM-1) (R&D Systems Inc., CV 3.1%, detection limit 1.26 ng/mL); soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) (R&D Systems Inc., CV 3.4%, detection limit 0.075 ng/mL); endothelial cell specific molecule 1 (ESM-1, or endocan) (OriGene Technologies, Inc., Rockville, MD, USA, CV 4.4%, detection limit < 10 pg/mL); ephrin-A1 (Wuhan Fine Biotech Co., CV < 8%, detection limit 0.094 ng/mL); ephrin receptor A2 (EphA2) (Wuhan Fine Biotech Co., CV < 8%, detection limit 46.875 pg/mL); and soluble urokinase-type plasminogen activator receptor (suPAR) (R&D Systems Inc., CV 4.6%, detection limit 33 pg/mL).

Techniques: Biomarker Discovery, Infection, Clinical Proteomics, Control, Membrane, Migration, Activation Assay

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis. Both anti-EphA2 and anti-CD44 antibodies did not recognize an irrelevant protein displayed on the yeast surface.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Recombinant, Flow Cytometry

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: (a) Comparison of the recovery of anti-EphA2 phage antibody 2D6 from yeast displaying EphA2 ECD (Y-EphA2) versus yeast displaying an irrelevant protein (Y-CON). A total of 1011 anti-EphA2 phage antibody 2D6 were incubated with each of the yeast displayed antigens. (b) Impact of the elution buffer on the titer of EphA2 phage antibody eluted from the surface of yeast displaying EphA2 ECD. A total of 1011 anti-EphA2 phage antibody 2D6 were incubated with each of the yeast displayed antigen proteins prior to elution. (c) The impact of input phage titer on eluted phage titer. The indicated titer of anti-EphA2 phage antibody 2D6 was incubated with yeast displayed EphA2 ECD or an irrelevant yeast displayed protein and the titer of eluted phage determined.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Comparison, Incubation

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: Recovery of specific phage antibody from yeast displayed antigens The indicated yeast displayed antigen was incubated with 10 9 phage and the titer of bound phage determined. Results are expressed as the ratio of output/input phage.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Incubation

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: (a) After two rounds of selection for internalization on the basal breast cancer cell line MDAMB231, the pool of phage antibodies was first incubated with irrelevant control yeast to remove any yeast binding antibodies followed by panning on yeast displaying either EphA2 ECD or CD44 domain 1. (b) The binding signal of the polyclonal phage antibody pool to EphA2 ECD or CD44 domain 1 after 2 rounds of panning was measured by using flow cytometry. The irrelevant control yeast was stained with unselected phage antibody library (R0), round 1 (R1) and round 2 (R2) polyclonal phage. (c) Frequency of antigen specific phage antibodies after one and two rounds of selection on yeast displayed antigen. Binding frequency was determined by analyzing 96 randomly picked phage antibodies for binding to yeast displayed antigen by flow cytometry. The induced yeast cells displaying an irrelevant protein, EphA2-ECD and CD44 domain 1 were stained with un-selected phage library (R0), polyclonal phages from R1 and R2 respectively. The un-induced yeast cells (yeast only), irrelevant phage antibody (phage control) and the un-selected phage antibody library were used as control.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Selection, Incubation, Control, Binding Assay, Flow Cytometry, Staining

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: Phage display scFv antibody selection on yeast displayed antigens Phage input and output ratios during the first and second rounds of selection on yeast displayed antigens.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Selection

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: (a) Binding of monoclonal phage antibodies to yeast displayed antigen domains as determined by flow cytometry. The induced yeast cells displaying an irrelevant protein (Y-CON), EphA2-ECD (Y-EphA2 ECD), CD44 link domain (Y-CD44 ECD D1) and CD44 full length ECD (Y-CD44 ECD) were stained with monoclonal phage antibodies isolated from Y-EphA2 and Y-CD44 D1 selections. (b) Binding of monoclonal phage antibodies to MDAMB231 cells as determined by flow cytometry, (c) differential binding of monoclonal phage antibodies to breast cancer cell lines including luminal breast cancer cell lines SUM52PE and MCF7, and basal breast cancer cell line MDAMB231.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Binding Assay, Flow Cytometry, Staining, Isolation

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: (a) Anti-EphA2 scFv 2D6 or D2-1A7 and anti-CD44 scFv F2-1A6 were used to immunoprecipitate their target antigen from MDAMB231 cells. Antigen was detected by Western blotting using either anti-EphA2 antibody D7 or anti-CD44 antibody Ab-4. (b) EphA2 antibodies D2-1A7 (□), D2-1A9 (◊), and 2D6 (○) compete with ephrin A1 for binding to MDAMB231 cells. Ability of phage antibodies D2-1A7, D2-1A9, and 2D6 binding to MDAMB231 cells in the presence of increasing concentrations of EphA2 ligand, Ephrin A1 was determined by flow cytometry.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Western Blot, Binding Assay, Flow Cytometry

Journal: Journal of molecular biology

Article Title: Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens

doi: 10.1016/j.jmb.2010.09.006

Figure Lengend Snippet: Cultured cells were incubated with irrelevant phage (A), anti-EphA2 phage D2-1A7 (B) and D2-1A9 (C), anti-CD44 phage F2-1A6 (D, E) for 3 hr at 37°C followed by glycine buffer wash. Panels D and E are from the same experiment, but E is imaged at higher magnification. Endocytosis was visulaized by detection of intracellular phage with anti-fd antibody, and analyzing by confocal microscopy.

Article Snippet: Specific binding to yeast displayed EphA2 and CD44 extracellular domains of the EphA2 natural ligand Ephrin A1, and antibodies to EphA2 and CD44 suggests that the domains are not only displayed but displayed in a form that can be specifically recognized by antibodies ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 caption a8 Display of antigen domains on the surface of yeast (a) The extracellular domain (ECD) of receptor EphA2 was displayed on yeast surface and recognized by anti-EphA2 antibody and recombinant mouse Ephrin A1 (R&D) as determined by flow cytometry analysis. (b) The link domain of CD44 (domain 1, or D1) was displayed on the yeast surface and recognized by anti-CD44 rabbit monoclonal antibody as determined by flow cytometry analysis.

Techniques: Cell Culture, Incubation, Confocal Microscopy

Journal: PLoS ONE

Article Title: Focused Examination of the Intestinal Epithelium Reveals Transcriptional Signatures Consistent with Disturbances in Enterocyte Maturation and Differentiation during the Course of SIV Infection

doi: 10.1371/journal.pone.0060122

Figure Lengend Snippet: Select list of differentially expressed genes in the Intestinal Epithelium at 21 days post SIV infection.

Article Snippet: Approximately, 23% of the transcripts included cell signaling genes (n = 70) such as Ephrin (EPH) receptor A2, EPH receptor B3, bone morphogenetic protein 6, ciliary neurotrophic factor receptor, interleukin 2 receptor, beta, delta-like 4 (Drosophila), opioid receptor, mu 1, dishevelled 2, mitogen-activated protein kinase kinase kinase 2, mitogen-activated protein kinase kinase 7, TRAF3-interacting JNK-activating modulator, interleukin 17 receptor C and SOCS1 (negative regulator of JAK-STAT pathway) .

Techniques: Infection